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A protein-truncating variant of CHEK2, 1100delC, is associated with a moderate increase in breast cancer risk. We have determined
the prevalence of this allele in index cases from 300 Australian multiple-case breast cancer families, 95% of which had been found to
be negative for mutations in BRCA1 and BRCA2. Only two (0.6%) index cases heterozygous for the CHEK2 mutation were identified.
All available relatives in these two families were genotyped, but there was no evidence of co-segregation between the CHEK2 variant
and breast cancer. Lymphoblastoid cell lines established from a heterozygous carrier contained approximately 20% of the CHEK2
1100delC mRNA relative to wild-type CHEK2 transcript. However, no truncated CHK2 protein was detectable. Analyses of
expression and phosphorylation of wild-type CHK2 suggest that the variant is likely to act by haploinsufficiency. Analysis of CDC25A
degradation, a downstream target of CHK2, suggests that some compensation occurs to allow normal degradation of CDC25A. Such
compensation of the 1100delC defect in CHEK2 might explain the rather low breast cancer risk associated with the CHEK2 variant,
compared to that associated with truncating mutations in BRCA1 or BRCA2.
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The CHEK2 tumour suppressor gene on chromosome 22q12.1
encodes a nuclear protein that is a member of the CDS1 subfamily
of serine/threonine protein kinases. In response to ionising
radiation (IR), threonine 68 of CHK2 is rapidly phosphorylated
by ataxia telangiectasia mutated (ATM) (Matsuoka et al, 2000;
Zhou et al, 2000), allowing oligomerisation and transautopho-
sphorylation of CHK2 (Ahn et al, 2002; Xu et al, 2002). Activated
CHK2 is involved in maintaining the G1/S and G2/M checkpoints
by phosphorylation of CDC25A, CDC25C and p53 (Chaturvedi
et al, 1999; Shieh et al, 2000; Falck et al, 2001), and repair of
double-strand DNA breaks via homologous recombination (HR)
through phosphorylation of BRCA1 (Lee et al, 2000). CHK2 is also
involved in the induction of p53-dependent apoptosis through
phosphorylation of p53 on Ser20 (Shieh et al, 2000), and, in a p53-
independent manner, via phosphorylation of PML and E2F1 (Lin
et al, 2001; Yang et al, 2002).
Somatic mutations of CHEK2 are rare in breast tumours
(Ingvarsson et al, 2002). However, a germline protein-truncating
variant of CHEK2, 1100delC, was first identified in a patient with
breast and colorectal cancer from a family with Li Fraumeni-like
syndrome (Bell et al, 1999; Miller et al, 2002). This variant was
subsequently found to be significantly associated with non-BRCA1/2
familial breast cancer, being present in 5.1% of cases and only
1.1% of controls (P¼0.00000003) (Meijers-Heijboer et al, 2002).
Among families with male breast cancer, CHEK2 1100delC was
present in 13.5% of cases (P¼00015). Meijers-Heijboer et al (2002)
estimated that the CHEK2 1100delC variant was associated with a
two-fold increased risk of female breast cancer, and a 10-fold
increased risk in men. However, additional studies of cohorts
collected in Finland, USA and UK suggest that CHEK2 1100delC is
not a risk factor for male breast cancer (Neuhausen et al, 2004;
Syrjakoski et al, 2004). Nevertheless, the high frequency of CHEK2
1100delC in families with multiple cases of breast cancer and
increased risk for female breast cancer has been substantiated by
several additional studies (Vahteristo et al, 2002; Offit et al, 2003;
Oldenburg et al, 2003). A consortium of nine case–control studies
that included 9154 cases and 9881 controls has found that the
CHEK2 1100delC variant is associated with a two-fold increased
risk of female breast cancer (P¼0.0000001) (CHEK2 Breast Cancer
Case-Control Consortium, 2004). The risk appears to be the
highest for contralateral breast cancer in CHEK2 1100delC carriers
who received radiation treatment for their first breast cancer
(Broeks et al, 2004). In the Netherlands, CHEK2 1100delC was
identified in 18% families with histories of both breast and
colorectal in contrast to only 4% of breast cancer families without
colorectal cancer. However, the suggestion that this mutant allele
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splays a role in susceptibility to both breast and colorectal cancer
(Meijers-Heijboer et al, 2003) has not been substantiated in a study
of patients with multiple colonic adenoma (Lipton et al, 2003).
The CHEK2 1100delC polymorphism results in a frameshift and
premature protein truncation, resulting in the deletion of the
kinase domain. The functional consequences of this deletion in a
heterozygous cell line are unknown at present. In one previous
study, a dramatically reduced expression of wild-type CHK2 was
detected in an lymphoblastoid cell line (LCL) derived from an
1100delC carrier (Dong et al, 2003). Two other studies found
markedly reduced expression of CHK2 in breast tumours from
CHK2 carriers, although this was not always accompanied by loss
of heterozygosity (LOH) at CHEK2 (Vahteristo et al, 2002;
Oldenburg et al, 2003). A significant proportion of sporadic breast
cancers also demonstrate a similar loss of expression of CHK2,
without carrying the CHEK2 1100delC variant (Sullivan et al,
2002). Here, we have assessed the frequency of CHEK2 1100delC
variant among familial breast cancer cases from Australia and have
analysed the expression, phosphorylation and activity of CHK2 in
LCLs from heterozygous individuals.
MATERIALS AND METHODS
Multiple-case breast cancer families
Multiple-case breast cancer families were ascertained through The
Kathleen Cuningham Consortium for Research into Familial Breast
Cancer (kConFab: http://www.kconfab.org). The eligibility criteria
for entry into kConFab for breast cancer families without a known
pathogenic or splice site mutation in BRCA1, BRCA2, PTEN
or TP53 are as follows: Criterion 1 – four or more cases of breast
or ovarian cancer, or Criterion 1B – two or three cases of breast or
ovarian cancer if at least one of these cases is ‘high risk’ (male
breast cancer, bilateral breast cancer, breast plus ovarian cancer,
or breast cancer at less than 40 years of age). Both criteria require
that two or more affected women are alive and that the families
have four or more living, adult, female, unaffected first- or second-
degree relatives of affected women; Criterion 4 – high-risk breast
cancer families (as defined by the National Breast Cancer Centre
Guidelines (http://www.nbcc.com.au)) from which fresh tissue is
available but who do not fit other kConFab criteria. This study has
the ethical committee approval from The Peter MacCallum Cancer
Centre and the Queensland Institute of Medical Research.
The index case, defined as the youngest available affected
individual in a family with blood available, was genotyped from a
total of 283 multiple-case families (212 Criteria 1, 61 Criteria 1B
and 10 Criterion 4), as well as 17 families that fitted Criteria 1
(n¼9) or 1B (n¼8) at the time of recruitment but who failed to
fulfil the criteria when collection was complete because of deaths
that occurred in the interim. In all, 286 out of 300 (95.3%) of these
families had undergone testing for BRCA1 and BRCA2 mutations
either by complete DNA sequencing (n¼108), or by a variety of
mutation detection methods (performed by the diagnostic
laboratories) that were considered to be at least 80% sensitive
(n¼176). BRCA1 and BRCA2 testing is pending in the remaining
16 families. Seven families contained one or more cases of male
breast cancer, 132 had one or more cases of bilateral female breast
cancer and 152 had at least one case of colorectal cancer.
Verification of all cancer diagnoses through medical records has
been achieved for 51% of the reported tumours. Two archival
paraffin blocks were available from CHEK2 1100delC carriers for
LOH analysis.
Genotyping
Genotyping was initially performed with the ABI PRISM 7700
(TaqMan) sequence detection system (Applied Biosystems, UK). A
two-stage PCR procedure was used to avoid amplification of
pseudogene sequences. Primers for the initial 537bp PCR were
(sequence differences between CHK2 and the pseudogene are
shown in lowercase): forward: gCAAAaTTAAATGTCcTAACTTGC;
reverse: GGCATGGTGGTGTGCatc. PCRs were carried out at 2mM
MgCl2 and 581C annealing temperature, with 20 cycles. In all, 3mg
of this PCR product was then used as template for the Taqman
assay (Applied Biosystems, UK) using 450nM primers (forward
primer: AGTAGGTGGGGGTTCCACATAAG; reverse primer:
GGCAGACTATGTTAATCTTTTTATTTTATGG) and an annealing
temperature of 621C. TAMRA probes, designed on the antisense
strand, were used at 225nM (C-allele (VIC): TGGAGTGCC
CAAAATCAgTAATCTAAAATT) and 75nM (delC-allele (FAM):
TGGAGTGCCCAAAATCATAATCTAAAATTC) concentration.
Loss of heterozygosity
Loss of heterozygosity was evaluated by macrodissection of the
tumour using a haematoxylin and eosin-stained slide as guide,
followed by direct sequencing using the outer primers. Loss of
heterozygosity was scored by absence of the allele in the
sequencing trace of the tumour, compared to its matching
germline.
Recombinant plasmids
Full-length CHK2 cDNA was cloned into pFLAG using the EcoR1
and HindIII sites. The 1100delC mutation was constructed using
the Quick Change mutagenesis kit (Stratagene, USA) using pFLAG-
CHK2 as a template with the following primers:
FOR_1100 – 50-GACTGTCTTATAAAGATTATGATTTTGGGCACT
CCAAG-30
REV_1100 –50-CTTGGAGTGCCCAAAATCATAATCTTTATAAGA
CAGTC-30
Cell culture and transfections
The wild-type control LCL (98.004.0039), CHEK2 1100delC
heterozygous (00.003.2070, 00.005.0442, 00.003.2053) LCLs and
293T fibroblasts were grown in RPMI 1640 with 10% foetal calf
serum, 100Uml
 1 penicillin and 100mgml
 1 streptomycin at
371C, 5% CO2.
293T fibroblasts were transfected with pFLAG or pFLAG-CHK2-
1100delC using PEI, as described previously (Boussif et al, 1995),
at 60–70% confluency and harvested 36h post-transfection.
RT–PCR and single-nucleotide primer extension analysis
of 1100delC mRNA transcript
Total RNA was extracted from the control and mutant LCLs using
the RNeasy Midi-kit (Qiagen, Australia). cDNA was transcribed
using Superscript III reverse transcriptase (Promega, Australia)
from 1mg total RNA primed with random hexamers. A 190bp PCR
product was amplified from the cDNA using the following primers:
forward: CCAGATGCTCTTGGCTGTGC; reverse: TAGGTGG
GGGTTCCACATAAGGT. The PCR product was sequenced directly
using the forward primer. Single-nucleotide primer extension
(SnuPE) reactions were carried out in a 50ml volume on 10ng of
purified PCR product using 10pmol of either forward
(GGACTGTCTTATAAAGATTA) or reverse (TCTTGGAGTGCC
CAAAATCA) primers using 1.0U of ampliTaq gold (Applied
Biosystems, Australia) in 1  PCR buffer and 1.6mM MgCl2, and
1mlo f
32P-dCTP,
32P-dTTP or
32P-dGTP (Amersham, Australia).
For each PCR product, four different reactions were carried out in
duplicate: two reactions with the forward primer with either
32P-
dCTP or
32P-dTTP as the radiolabel, and two reactions for the
reverse primer with either
32P-dGTP or
32P-dTTP as the radiolabel.
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and 721C for 2min, after which 50ml of formamide-loading buffer
was added to each reaction. The samples were then heated to 951C
for a further 5min and 5ml loaded on a 6% sequencing gel, which
was run at 1000V for about 2h, dried and exposed to film.
Proteasome inhibition
The wild-type control (98.004.0039) and 1100delC heterozygous
(00.003.2070) LCLs were treated with 10mgml
 1 N-acetyl-leucyl-
leucyl-norleucinal (ALLN) (Sigma-Aldrich, Australia) in RPMI
1640 with 10% foetal calf serum, 100Uml
 1 penicillin and
100mgml
 1 streptomycin and grown at 371C, 5% CO2. The cells
were harvested at the indicated timepoints and protein extracts
prepared.
Protein extracts and Western blotting
Cells were mock or treated with 6Gy of IR (
137Cs) and harvested
after 30min. Cell extracts were prepared by lysis in Universal
immunoprecipitation buffer (50mM Tris–HCl, pH 7.4, 150mM
NaCl, 2mM EDTA, 25mM NaF, 25mM b-glycerophosphate, 0.1mM
sodium orthovanadate, 0.1mM phenylmethylsulphonyl fluoride,
5mgml
 1 leupeptin, 1mgml
 1 aprotinin, 0.2% Triton X-100, 0.3%
IGEPAL). In all, 50mg of cell extract was separated by SDS–PAGE,
transferred to nitrocellulose and membranes probed with any of
the following: a-CHK2 Thr68-P (Cell Signalling, USA), a-CHK2
(N17, H300, Santa Cruz, USA), a-CDC25A F6 (Santa Cruz, USA),
a-PP2A-Ab (C-20,Cell Signalling, USA), a-p53 D01 (Novacastra
Laboratories, UK), a-p53 Ser15-P (Cell Signalling, USA), polyclonal
a-ATM (residues 250–522) (Chenevix-Trench et al, 2002).
RESULTS
Genotyping and LOH analysis
CHEK2 1100delC heterozygosity was identified in two out of 300
(0.6%) of index cases, in two families. Both of these families fitted
Criteria 1B. All available male and female relatives (n¼18) were
then genotyped for the variant. Family 0011.00.005 had three cases
of breast cancer, two of which were bilateral. Only these two
bilateral cases were available for genotyping, and only one was a
carrier of 1100delC. Family 0026.00.003 had three cases of breast
cancer, two of whom (one with bilateral and the other with
unilateral disease) were carriers. However, the variant was
inherited from a parent with no personal or ancestral history of
breast cancer, and not from the parent with an affected sister.
Neither of these families contained cases of male breast cancer or
colorectal cancer. Two tumours were available for LOH analysis, of
which one showed loss of the wild-type allele and the other of the
variant allele (data not shown).
The 1100delC mRNA transcript is present in LCLs at a
reduced level compared to the wild-type CHK2 transcript
To determine the functional effect of CHEK2 1100delC truncation,
we established LCLs from three female CHEK2 1100delC carriers,
00.003.2053 (unaffected at age 54), 00.003.2070 (unaffected at age
79 and no family history of breast cancer except in her daughter
and granddaughter) and 00.005.0442 (breast cancer at age 52), as
well as LCLs from healthy wild-type individuals (98.004.0039) as
controls. To test whether mRNA encoding CHEK2 1100delC was
present in the LCLs, cDNA was prepared from wild-type and
heterozygous LCLs, and a 190bp region covering the open reading
frame of CHEK2 1100delC was amplified. Direct sequencing of the
product confirmed the existence of mutant transcript although its
level appeared to be markedly reduced compared to the wild-type
transcript (Figure 1A).
We then used SnuPE to compare the relative levels of the
1100delC mRNA to wild-type mRNA in the heterozygous LCLs.
PCR products from the control (98.004.0039) and heterozygous
LCLs extended the forward primer with
32P-dCTP and the reverse
primer with
32P-dGTP, which is specific for the wild-type
transcript (Figure 1B). Using
32P-dTTP, which is specific for the
1100delC transcript, the forward and reverse primers were only
extended in the heterozygous LCLs (Figure 1B). When plasmid
DNA containing the 1100delC mutant was used as template, the
primer is extended only by
32P-dTTP and not
32P-dCTP or
32P-
dGTP.
Densitometric analysis of the results obtained from the three
heterozygous LCLs showed that the level of the 1100delC transcript
was approximately 20% of the normal transcript (Figure 1C).
CHK2 1100delC protein is not detectable in heterozygous
LCLs
The 1100delC mutation induces a frameshift starting at codon 366
with subsequent truncation of the protein at amino acid 380,
resulting in a protein product of approximately 52kDa (in silico
analysis using SwisProt). Antibodies directed against the N-
terminal regions of CHK2 (N17 and H300) were used to analyse
cell extracts from heterozygous LCLs for full-length CHK2 (62kDa)
and the truncated protein product (52kDa). Only the full-length
CHK2 protein was detectable by Western analysis and immuno-
precipitation (data not shown).
The absence of the truncated protein suggests that it is either
unstable or not translated. To evaluate protein stability, one
control (98.004.0039) and one heterozygous 1100delC LCL
(00.003.2070) were treated with 10mgml
 1 of the proteasome
inhibitor, ALLN, and harvested at 0, 4, 16 and 24h after treatment.
Cell lysates were prepared and analysed by Western blotting with
the H300 CHK2 antibody. Cell extracts from 293T cells over-
expressing FLAG-tagged CHK2-1100delC were used as a positive
control to detect the truncated protein. During the course of
treatment with ALLN, the levels of endogenous, wild-type CHK2
did not increase in either the control or heterozygous LCLs. Also,
no truncated protein was detected in the CHK2-1100delC
heterozygous LCL (Figure 2), suggesting that the truncated protein
is not translated. However, it remains possible that a small
proportion of CHK2-1100delC is present in these cells, but below
the sensitivity of our detection method.
Response of the 1100delC LCLs to DNA damage
To determine if the response of CHK2 to IR is impaired in
heterozygous LCLs, phosphorylation of CHK2 on Thr68 and
degradation of its downstream target CDC25A were studied by
Western blot analysis of cell extracts prepared before, and after,
exposure to 6Gy of IR (Figure 3A). Three heterozygous 1100delC
LCLs were compared with three control cell lines (data are shown
for only one representative control). As expected, the control cell
lines showed a marked phosphorylation of CHK2 after IR, whereas
heterozygous LCLs from 1100delC carriers exhibited a markedly
reduced phosphorylation of CHK2 Thr68. This reduction in the
level of Thr68 phosphorylation after IR is presumably due to the
reduction in the amount of total full-length CHK2 protein seen in
these cells, detected with the CHK2 N17 antibody (Figure 3A),
compared with PP2A, a loading control.
Owing to the reduced level of endogenous CHK2 in the
heterozygous LCLs, we also investigated the downstream effects
of CHK2 activation. CHK2 is involved in the intra-S-phase
checkpoint that, in response to IR, results in degradation of
CDC25A (reviewed in Bartek and Lukas, 2003). We evaluated
CDC25A degradation after IR in wild-type and heterozygous LCLs,
but found that there was no significant difference between them
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s(Figure 3A), which indicates that signalling downstream of CHK2
is not compromised in heterozygous LCLs.
To ensure that the reduction in Thr68 phosphorylation of CHK2
was not due to an ATM defect upstream of CHK2, but was only a
result of the decreased levels of CHK2, we investigated ATM
phosphorylation of p53 at Ser15 as a measure of in vivo ATM
activity (Banin et al, 1998; Canman et al, 1998; Khanna et al, 1998).
Phosphorylation of p53 on Ser15 was similar between the control
and heterozygous 1100delC LCLs, as was the level of ATM in these
cells (Figure 3B). In addition, the stabilisation of p53 after IR was
normal in the heterozygous LCLs compared to controls (Figure 3B),
an event that is attributed to CHK2 phosphorylation of p53 on
Ser20 (Chehab et al, 2000; Shieh et al, 2000).
Overexpression of the 1100delC mutant does not affect
endogenous Chk2 phosphorylation
We performed functional analysis of the CHEK2 1100delC variant
by ectopically expressing it in 293T cells to assess whether it
undermined the phosphorylation and function of endogenous
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Figure 1 The 1100delC mRNA transcript is present in mutant LCLs at a reduced level compared to wild-type CHEK2. (A) cDNA sequence electrograms
of the PCR products with arrows showing the position of 1100delC variation in heterozygous LCLs. Sequences are presented in the 50–30 direction. (B)
Autoradiograph of SnuPE reactions from wild-type and heterozygous LCLs with both forward and reverse primers. (C) Quantitation of 1100delC
expression in the three heterozygous LCLs. The mean of the duplicates was calculated and the level of the 1100delC mRNA was expressed as a ratio of the
variant compared to wild type in both the forward and reverse directions.
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sCHK2. Western blot analysis of cell extracts with anti-phospho
Thr68 antibody revealed that the overexpression of the variant
(detected with the H300 antibody) did not interfere with
phosphorylation of endogenous CHK2 after IR, compared to
vector-only transfected cells (Figure 4). The variant protein is
clearly overexpressed, but is phosphorylated on Thr68 at markedly
reduced levels compared to that of wild-type, endogenous CHK2.
Dimerisation is proposed to represent an important step in the
regulation of CHK2 activity (Ahn et al, 2002; Xu et al, 2002).
However, we were not able to detect dimerisation of variant
protein with the wild-type CHK2 in cells that ectopically expressed
both proteins (data not shown), indicating that the truncated
protein is not likely to affect wild-type CHK2 activity in this way,
even if it is expressed at very low levels (undetectable with our
methodology).
DISCUSSION
The CHEK2 1100delC variant has been reported in 30 out of 718
(5.1%) multiple-case families from Europe and the USA (Meijers-
Heijboer et al, 2002). The frequency of the variant in controls
ranges from about 1.3% in the Netherlands and Finland to 0.52%
in UK and to about 0.2% in Germany (CHEK2 Breast Cancer Case-
Control Consortium, 2004). In Australia, the prevalence of the
mutation is lower in 10 out of 1474 (0.68%) female breast cancer
cases and one out of 736 (0.14%) controls (CHEK2 Breast Cancer
Case-Control Consortium, 2004). This study shows that only two
out of 300 (0.6%) of index cases from multiple-case breast cancer
families from Australia carry the variant.
CHEK2 1100delC has been reported in 18% of Hereditary Breast
and Colorectal Cancer families from the Netherlands (Meijers-
Heijboer et al, 2003). Our study of index cases from multiple-case
breast cancer families included 152 who had first-, second- or
third-degree relatives with colorectal cancer, as well as seven with
male relatives affected with breast cancer, but the CHEK2 variant
was not identified in any of these index cases. Both families that
carried the CHEK2 1100delC variant contained cases of bilateral
breast cancer. However, bilateral cancer is not unusual in the
multicase families recruited by kConFab, and the association
between CHEK2 1100delC may be coincidental.
As only two families were identified with the CHEK2 1100delC
variant, there was insufficient power to analyse the penetrance of
the variant in these families, or to carry out any histopathological
or clinical follow-up studies. Loss of heterozygosity analysis
showed that in one tumour loss of the wild-type allele occurred,
and in the second tumour there was loss of the variant. This is
consistent with other reports that loss of either the wild-type or
variant allele can occur (Vahteristo et al, 2002; Oldenburg et al,
2003).
Although a number of genetic studies have been carried out with
CHEK2 1100delC allele, to date no functional analysis has been
performed using heterozygous LCLs. In the present study, we
examined the mRNA and protein expression of CHK2 1100delC
variant. Mutant mRNA represented about 20% of the total CHK2
transcript, demonstrating that variant message is present but may
pFLAG-1100delC
98.004.0039
NS
CHK2
F-1100delC
00.003.2070
0 4 16 24 0 4 16 24 Hours
WB: CHK2 (H300)
Figure 2 CHK2-1100delC is not detectable after proteasome inhibition.
The indicated LCLs were untreated (0) or treated with 10mgml
 1 of
ALLN for indicated times. Cell extracts were resolved by SDS–PAGE and
immunoblotted with the CHK2 (H300) antibody. The stabilised band (top)
is a nonspecific (NS) band detected with this antibody.
A
B
–
98.004.0039 (wt)
00.003.2070 (1100delC)
00.005.0442 (1100delC)
00.003.2053 (1100delC)
+–+–+ –+
WB: CHK2 (Thr68-P)
IR
WB: CHK2 (N17)
WB: CDC25A (F6)
WB: PP2A-A (C-20)
–+ –+ –+
98.004.0039 (wt)
00.003.2070 (1100delC)
00.005.0442 (1100delC)
00.003.2053 (1100delC)
– IR +
WB: ATM
WB: p53 (Ser15-P)
WB: p53 (DO1)
Figure 3 Response of the heterozygote 1100delC LCLs to DNA
damage. (A, B) Lymphoblastoid cell lines from healthy control and
heterozygous individuals were either mock-treated or treated with 6Gy of
IR and harvested after 30min. Cell extracts were prepared and
immunoblotted with the indicated antibodies.
WB: CHK2 (Thr68-P)
pFLAG-1100delC
pFLAG
WB: CHK2 (H300)
F-1100delC
CHK2
F-1100delC
CHK2
IR – + – +
Figure 4 Overexpression of FLAG-CHK2-1100delC does not affect
endogenous CHK2 function. 293T fibroblasts were transfected with either
pFLAG or pFLAG-CHK2-1100delC and incubated for 36h. The cells were
either mock-treated or treated with 6Gy of IR and harvested after 30min.
Protein extracts were prepared and Western blotting performed using the
indicated CHK2 antibodies.
CHEK2 1100delC variant and breast cancer risk
CR Jekimovs et al
788
British Journal of Cancer (2005) 92(4), 784–790 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sundergo nonsense-mediated decay. Notably, we were unable to
detect 1100delC protein in heterozygous LCLs although several
methods (Western blotting, immunoprecipitation and proteasome
inhibitor treatment) were employed. The amount of total CHK2
protein, and phosphorylation of CHK2 on Thr68, in heterozygous
LCLs was reduced to about half compared to wild-type LCLs,
suggesting that 1100delC variant may act simply by haploinsuffi-
ciency. The increased breast cancer risk associated with CHEK2
1100delC may therefore be attributed to a threshold level of
phosphorylation of CHK2 below which cells become more
susceptible to other genetic and environmental factors promoting
tumorigenesis. Consistent with this, we were not able to
demonstrate any dominant interfering affect of 1100delC variant
when ectopically expressed in 293T cells. Furthermore, although
full-length CHK2 expression and Thr68 phosphorylation were
considerably reduced in heterozygous LCLs, degradation of
Cdc25A (a downstream target of CHK2) was normal. This may
be due to compensation of CHK2 function by CHK1, which has
redundant functions in targeting the same substrates. Compensa-
tion of the 1100delC defect in CHK2 by CHK1, or any other
mechanism, might explain the rather low breast cancer risk
associated with the CHEK2 variant, compared to that associated
with truncating mutations in BRCA1 or BRCA2.
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